M A Deltenre

Brugmann University Hospital, Brussels, Belgium.

3 publications 1997 – 2012
Helicobacter InfectionsCost-Benefit AnalysisHelicobacter pylori

What does M A Deltenre research?

Dr. Deltenre studies how treating peptic ulcers caused by Helicobacter pylori can be made more effective and cost-efficient. By analyzing the costs associated with different treatment options, they explore how eradicating this specific bacteria can not only alleviate the suffering of patients but also save considerable money for healthcare systems. Their work emphasizes the importance of addressing both the health and financial aspects of peptic ulcer disease.

Key findings

  • Eradication therapy for H. pylori can save between $750,000 and $1,000,000 annually for every million people in Western Europe.
  • Using eradication therapy instead of ongoing treatments provides a more cost-effective method for managing peptic ulcers.
  • The approach significantly reduces the recurrence of peptic ulcers, leading to better patient outcomes and lower healthcare costs.

Frequently asked questions

Does Dr. Deltenre study peptic ulcers?
Yes, Dr. Deltenre specifically researches the treatment of peptic ulcers caused by Helicobacter pylori.
What treatments has Dr. Deltenre researched?
They focus on H. pylori eradication therapy as a primary treatment to effectively manage peptic ulcers.
Is Dr. Deltenre's work relevant to patients suffering from peptic ulcers?
Yes, their research directly benefits patients by highlighting more effective and cost-saving treatment options.

Publications in plain English

Economics of Helicobacter pylori eradication therapy.

2012

European journal of gastroenterology & hepatology

Deltenre MA

Plain English
This research looked at the costs and benefits of treating peptic ulcers caused by the bacteria Helicobacter pylori. It found that using H. pylori eradication therapy could save between $750,000 and $1,000,000 each year for every million people in Western Europe, compared to ongoing or temporary treatments. This matters because eradicating the bacteria not only helps patients feel better but also reduces overall medical costs associated with peptic ulcer disease. Who this helps: Patients suffering from peptic ulcers and healthcare systems.

PubMed

Panel discussion.

2012

European journal of gastroenterology & hepatology

Lam SK, Gasbarrini G, Malfertheiner P, Tytgat GN, Deltenre MA

PubMed

Economics of Helicobacter pylori eradication therapy.

1997

European journal of gastroenterology & hepatology

Deltenre MA

Plain English
This study looked at the financial impact of treating peptic ulcers caused by the Helicobacter pylori bacteria. It found that using eradication therapy could save up to $1 million annually for every million people in western Europe, compared to ongoing treatments. This is important because it highlights a more cost-effective way to manage a common and recurring health issue that also significantly reduces relapses. Who this helps: This helps patients with peptic ulcers and healthcare providers.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.